Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Guadecitabine + Durvalumab for Liver and Pancreatic Cancer
Recruiting1 awardPhase 1
Newport Beach, California
This trial is testing the side effects and best dosage of a new cancer drug, guadecitabine, when given with another drug, durvalumab. Guadecitabine works by blocking enzymes needed for cell growth, and durvalumab works by targeting certain cells. The hope is that the two drugs will work better together than either does alone in treating liver, pancreatic, bile duct, or gallbladder cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service